Cann Reaffirms “Hold” Rating for Crispr Therapeutics (CRSP)

Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “hold” rating reissued by Cann in a research note issued to investors on Sunday.

The analysts wrote, “CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018.””

A number of other equities analysts also recently issued reports on CRSP. Oppenheimer began coverage on Crispr Therapeutics in a research note on Thursday. They set a “hold” rating for the company. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Chardan Capital reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. SunTrust Banks reiterated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Barclays reiterated a “buy” rating and set a $29.00 price target on shares of Crispr Therapeutics in a research note on Friday, September 8th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $22.38.

Shares of Crispr Therapeutics (CRSP) traded down $0.26 during trading on Friday, reaching $18.88. The company had a trading volume of 272,599 shares, compared to its average volume of 282,198. Crispr Therapeutics has a twelve month low of $11.63 and a twelve month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. Crispr Therapeutics’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter last year, the firm posted ($2.77) EPS. equities analysts anticipate that Crispr Therapeutics will post -2.46 earnings per share for the current fiscal year.

In other news, Director Thomas Woiwode sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $20.21, for a total value of $34,357.00. Following the transaction, the director now owns 8,218 shares in the company, valued at approximately $166,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $18.98, for a total value of $21,114,225.08. The disclosure for this sale can be found here. Insiders have sold a total of 1,935,654 shares of company stock valued at $36,843,188 in the last quarter. Company insiders own 39.98% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Wells Fargo & Company MN boosted its stake in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth approximately $193,000. Ark Investment Management LLC purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $206,000. Moloney Securities Asset Management LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth approximately $235,000. Finally, Vanguard Group Inc. purchased a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $273,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.

WARNING: “Cann Reaffirms “Hold” Rating for Crispr Therapeutics (CRSP)” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/10/cann-reaffirms-hold-rating-for-crispr-therapeutics-crsp.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply